Epstein-Barr Virus, Nuclear Antigen IgG (EBNA IgG, Serum)
The study is aimed at detecting IgG class antibodies to the EBV nuclear antigen (EBNA).
Used for confirming past infection and assessing the formation of lasting immunity.
EBNA IgG antibodies are not detected in the acute phase of infection.
Applied for differential diagnosis of EBV infection stages, determining the latent virus status, and assessing immune response after past infection.
Included in comprehensive examination when chronic or latent EBV infection is suspected.
What the test assesses:
– Presence of IgG antibodies to the EBV nuclear antigen.
– Fact of past infection.
– Lasting immune response to EBV, confirming the completed infection phase.
Biomaterial: Venous blood (serum)
– Submit fasting (8-12 hours after the last meal).
– Drinking still water is allowed.
Medications:
– Antibacterial medication intake does not affect the result.
– Immunoglobulins and immunomodulators may distort indicators.
– The doctor should be informed about all medications taken.
Recommended for testing:
– To clarify the EBV infection stage and differentiate acute and latent forms.
– When immune status assessment is needed.
– When examining patients with immunodeficiencies or immune response disorders.
– With prolonged changes in complete blood count, lymphoproliferative conditions.
– Positive result (EBNA IgG detected): indicates past EBV infection and formed immunity; does not indicate the acute disease phase.
– Negative result (EBNA IgG not detected): no evidence of past infection; characteristic of acute primary infection (in combination with VCA IgM/IgG).
Important — for correct interpretation, it is recommended to assess the result together with VCA IgM, VCA IgG, and EA IgG, especially when differentiating infection stages.
